Patents by Inventor Shu-Hui Liu

Shu-Hui Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11183487
    Abstract: A packaged semiconductor device including an integrated passive device-containing package component disposed between a power module and an integrated circuit-containing package and a method of forming the same are disclosed. In an embodiment, a device includes a first package component including a first integrated circuit die; a first encapsulant at least partially surrounding the first integrated circuit die; and a redistribution structure on the first encapsulant and coupled to the first integrated circuit die; a second package component bonded to the first package component, the second package component including an integrated passive device; and a second encapsulant at least partially surrounding the integrated passive device; and a power module attached to the first package component through the second package component.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: November 23, 2021
    Assignee: Taiwan Semiconductor Manufacturing Company, Ltd.
    Inventors: Chi-Hui Lai, Shu-Rong Chun, Kuo-Lung Pan, Tin Hao Kuo, Hao-Yi Tsai, Chung-Shi Liu, Chen-Hua Yu, Yu-Chia Lai
  • Patent number: 11121070
    Abstract: A device includes a package. The package includes a plurality of dies, an encapsulant encapsulating the plurality of dies, and a redistribution structure over the plurality of dies and the encapsulant. The device further includes first sockets bonded to a top surface of the redistribution structure and a rigid/flexible substrate bonded to the top surface of the redistribution structure. The rigid/flexible substrate includes a first rigid portion, a second rigid portion, and a flexible portion interposed between the first rigid portion and the second rigid portion. The device further includes second sockets bonded to the first rigid portion of the rigid/flexible substrate and connector modules bonded to the second rigid portion of the rigid/flexible substrate.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 14, 2021
    Assignee: Taiwan Semiconductor Manufacturing Company, Ltd.
    Inventors: Shu-Rong Chun, Tin-Hao Kuo, Chi-Hui Lai, Kuo Lung Pan, Hao-Yi Tsai, Chung-Shi Liu, Chen-Hua Yu
  • Patent number: 11107771
    Abstract: A method includes encapsulating a plurality of package components in an encapsulant, and forming a first plurality of redistribution layers over and electrically coupling to the plurality of package components. The first plurality of redistribution layers have a plurality of power/ground pad stacks, with each of the plurality of power/ground pad stacks having a pad in each of the first plurality of redistribution layers. The plurality of power/ground pad stacks include a plurality of power pad stacks, and a plurality of ground pad stacks. At least one second redistribution layer is formed over the first plurality of redistribution layers. The second redistribution layer(s) include power lines and electrical grounding lines electrically connecting to the plurality of power/ground pad stacks.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: August 31, 2021
    Assignee: Taiwan Semiconductor Manufacturing Company, Ltd.
    Inventors: Shu-Rong Chun, Tin-Hao Kuo, Chi-Hui Lai, Kuo Lung Pan, Yu-Chia Lai, Hao-Yi Tsai, Chung-Shi Liu, Chen-Hua Yu
  • Patent number: 11091544
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 17, 2021
    Assignee: Rinat Neuroscience Corp.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Publication number: 20210115159
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Application
    Filed: November 18, 2020
    Publication date: April 22, 2021
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
  • Patent number: 10941216
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: March 9, 2021
    Assignee: Pfizer Inc.
    Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
  • Patent number: 10927178
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 23, 2021
    Assignee: PFIZER INC.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
  • Publication number: 20200102394
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Applicant: PFIZER INC.
    Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
  • Patent number: 10421815
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: September 24, 2019
    Assignee: Pfizer Inc.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
  • Publication number: 20190092867
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Application
    Filed: October 22, 2018
    Publication date: March 28, 2019
    Applicant: PFIZER INC.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Weihsien Ho
  • Publication number: 20190002559
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 3, 2019
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Patent number: 10144781
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 4, 2018
    Assignee: Pfizer Inc.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
  • Patent number: 10100114
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 16, 2018
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Publication number: 20180002428
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Application
    Filed: May 31, 2017
    Publication date: January 4, 2018
    Applicant: PFIZER INC.
    Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Weihsien HO
  • Publication number: 20170313787
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 2, 2017
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
  • Patent number: 9708405
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: July 18, 2017
    Assignee: PFIZER INC.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
  • Patent number: 9676871
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: June 13, 2017
    Assignees: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
  • Publication number: 20160257746
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 8, 2016
    Inventors: Shu-Hui LIU, Wei-Hsien HO, Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David Louis SHELTON, Thomas-Toan TRAN
  • Patent number: 9399074
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 26, 2016
    Assignee: Rinat Neuroscience Corp.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Publication number: 20150175701
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 25, 2015
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski